Literature DB >> 27438654

Unique and Redundant Functions of p70 Ribosomal S6 Kinase Isoforms Regulate Mesenchymal Cell Proliferation and Migration in Pulmonary Fibrosis.

Satish K Madala1, Vishwaraj Sontake1, Ramakrishna Edukulla1, Cynthia R Davidson1, Stephanie Schmidt1, William D Hardie1.   

Abstract

The p70 ribosomal S6 kinase (p70S6K) is a downstream substrate that is phosphorylated and activated by the mammalian target of rapamycin complex and regulates multiple cellular processes associated with pulmonary fibrogenesis. Two isoforms of the p70S6K have been identified (S6K1 and S6K2), but their relative contributions in mediating pulmonary fibrosis are unknown. To interrogate the roles of the p70S6K isoforms, we overexpressed transforming growth factor (TGF)-α in mice deficient for the S6K1 or S6K2 genes and measured changes in lung histology, morphometry, total lung collagen, lung function, and proliferation between wild-type and isoform-deficient mice. Deficiency of S6K1, but not S6K2, had a significant effect on reducing proliferation in subpleural fibrotic lesions during TGF-α-induced fibrosis. Migration was significantly decreased in mesenchymal cells isolated from the lungs of S6K1 knockout mice compared with wild-type or S6K2 knockout mice. Conversely, increases in subpleural thickening were significantly decreased in S6K2-deficient mice compared with wild type. Deficiency of S6K2 significantly reduced phosphorylation of the downstream S6 ribosomal protein in lung homogenates and isolated mesenchymal cells after TGF-α expression. However, deficiency of neither isoform alone significantly altered TGF-α-induced collagen accumulation or lung function decline in vivo. Furthermore, deficiency in neither isoform prevented changes in collagen accumulation or lung compliance decline after administration of intradermal bleomycin. Together, these findings demonstrate that the p70S6K isoforms have unique and redundant functions in mediating fibrogenic processes, including proliferation, migration, and S6 phosphorylation, signifying that both isoforms must be targeted to modulate p70S6K-mediated pulmonary fibrosis.

Entities:  

Keywords:  mammalian target of rapamycin; p70 ribosomal S6 kinase; pleural disease; pulmonary fibrosis

Mesh:

Substances:

Year:  2016        PMID: 27438654      PMCID: PMC5248954          DOI: 10.1165/rcmb.2016-0090OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  46 in total

1.  Distinct characteristics of pleuroparenchymal fibroelastosis with usual interstitial pneumonia compared with idiopathic pulmonary fibrosis.

Authors:  Tsuneyuki Oda; Takashi Ogura; Hideya Kitamura; Eri Hagiwara; Tomohisa Baba; Yasunori Enomoto; Tae Iwasawa; Koji Okudela; Tamiko Takemura; Fumikazu Sakai; Yoshinori Hasegawa
Journal:  Chest       Date:  2014-11       Impact factor: 9.410

2.  Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells.

Authors:  O E Pardo; A Arcaro; G Salerno; T D Tetley; T Valovka; I Gout; M J Seckl
Journal:  Oncogene       Date:  2001-11-15       Impact factor: 9.867

Review 3.  The S6K protein family in health and disease.

Authors:  Mariana R Tavares; Isadora C B Pavan; Camila L Amaral; Letícia Meneguello; Augusto D Luchessi; Fernando M Simabuco
Journal:  Life Sci       Date:  2015-03-26       Impact factor: 5.037

Review 4.  Signaling pathways in the epithelial origins of pulmonary fibrosis.

Authors:  William D Hardie; James S Hagood; Vrushank Dave; Anne-Karina T Perl; Jeffrey A Whitsett; Thomas R Korfhagen; Stephan Glasser
Journal:  Cell Cycle       Date:  2010-07-03       Impact factor: 4.534

5.  MEK-ERK pathway modulation ameliorates pulmonary fibrosis associated with epidermal growth factor receptor activation.

Authors:  Satish K Madala; Stephanie Schmidt; Cynthia Davidson; Machiko Ikegami; Susan Wert; William D Hardie
Journal:  Am J Respir Cell Mol Biol       Date:  2011-10-20       Impact factor: 6.914

6.  Conditional expression of transforming growth factor-alpha in adult mouse lung causes pulmonary fibrosis.

Authors:  William D Hardie; Timothy D Le Cras; Kenny Jiang; Jay W Tichelaar; Mohamad Azhar; Thomas R Korfhagen
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-12-05       Impact factor: 5.464

7.  Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer cells.

Authors:  Olivier E Pardo; Adeline Lesay; Alexandre Arcaro; Rita Lopes; Bee Ling Ng; Patricia H Warne; Iain A McNeish; Teresa D Tetley; Nicholas R Lemoine; Huseyin Mehmet; Michael J Seckl; Julian Downward
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

8.  Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy.

Authors:  Julie R McMullen; Tetsuo Shioi; Li Zhang; Oleg Tarnavski; Megan C Sherwood; Adam L Dorfman; Sarah Longnus; Mario Pende; Kathleen A Martin; John Blenis; George Thomas; Seigo Izumo
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

9.  Enhanced migration of fibroblasts derived from lungs with fibrotic lesions.

Authors:  H Suganuma; A Sato; R Tamura; K Chida
Journal:  Thorax       Date:  1995-09       Impact factor: 9.139

10.  Dual targeting of MEK and PI3K pathways attenuates established and progressive pulmonary fibrosis.

Authors:  Satish K Madala; Ramakrishna Edukulla; Mukta Phatak; Stephanie Schmidt; Cynthia Davidson; Thomas H Acciani; Thomas R Korfhagen; Mario Medvedovic; Timothy D Lecras; Kimberly Wagner; William D Hardie
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

View more
  6 in total

1.  Repetitive intradermal bleomycin injections evoke T-helper cell 2 cytokine-driven pulmonary fibrosis.

Authors:  Brijendra Singh; Rajesh K Kasam; Vishwaraj Sontake; Thomas A Wynn; Satish K Madala
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-03       Impact factor: 5.464

2.  Wilms' tumor 1 drives fibroproliferation and myofibroblast transformation in severe fibrotic lung disease.

Authors:  Vishwaraj Sontake; Rajesh K Kasam; Debora Sinner; Thomas R Korfhagen; Geereddy B Reddy; Eric S White; Anil G Jegga; Satish K Madala
Journal:  JCI Insight       Date:  2018-08-23

3.  Activation of p70S6 Kinase-1 in Mesenchymal Stem Cells Is Essential to Lung Tissue Repair.

Authors:  Katsuyuki Takeda; Fangkun Ning; Joanne Domenico; Masakazu Okamoto; Shigeru Ashino; Sang-Ha Kim; Yi Yeong Jeong; Yoshiki Shiraishi; Naohiro Terada; Everett Rand Sutherland; Erwin W Gelfand
Journal:  Stem Cells Transl Med       Date:  2018-05-05       Impact factor: 6.940

4.  Akt signaling is activated by TGFβ2 and impacts tenogenic induction of mesenchymal stem cells.

Authors:  Sophia K Theodossiou; Jett B Murray; LeeAnn A Hold; Jeff M Courtright; Anne M Carper; Nathan R Schiele
Journal:  Stem Cell Res Ther       Date:  2021-01-26       Impact factor: 6.832

5.  Oxyresveratrol Inhibits IL-1β-Induced Inflammation via Suppressing AKT and ERK1/2 Activation in Human Microglia, HMC3.

Authors:  Phateep Hankittichai; Hua Jane Lou; Nitwara Wikan; Duncan R Smith; Saranyapin Potikanond; Wutigri Nimlamool
Journal:  Int J Mol Sci       Date:  2020-08-22       Impact factor: 5.923

6.  Inhibition of Aurora Kinase B attenuates fibroblast activation and pulmonary fibrosis.

Authors:  Rajesh K Kasam; Sudhir Ghandikota; Divyalakshmi Soundararajan; Geereddy B Reddy; Steven K Huang; Anil G Jegga; Satish K Madala
Journal:  EMBO Mol Med       Date:  2020-08-06       Impact factor: 12.137

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.